IMUX – immunic, inc. (US:NASDAQ)
Stock Stats
News
Immunic (IMUX) is now covered by Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
Form SCHEDULE 13G IMMUNIC, INC. Filed by: Deep Track Capital, LP
Form D IMMUNIC, INC.
Form DEF 14A IMMUNIC, INC. For: Apr 14
Form 3 IMMUNIC, INC. For: Feb 17 Filed by: BVF I GP LLC
Form 3 IMMUNIC, INC. For: Feb 17 Filed by: Nagel Robert Thorvald
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.